A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator s Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Grants and Contracts Details

StatusActive
Effective start/end date12/15/217/31/23

Funding

  • Genmab US Incorporated: $20,826.00